Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

Algernon Pharmaceuticals (AGN)

Algernon Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:CSE:AGN
DateTimeSourceHeadlineSymbolCompany
11/02/202113:00InvestorsHub NewsWireAlgernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study ProtocolCSE:AGNAlgernon Pharmaceuticals Inc
04/06/202017:41InvestorsHub NewsWireAlgernon Receives U.S. FDA Clearance for Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19CSE:AGNAlgernon Pharmaceuticals Inc
13/04/202014:44InvestorsHub NewsWireAlgernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) HowardCSE:AGNAlgernon Pharmaceuticals Inc
13/03/202012:40InvestorsHub NewsWireAlgernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and EmergencyCSE:AGNAlgernon Pharmaceuticals Inc
06/03/202013:32InvestorsHub NewsWireAlgernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for CoronavirusCSE:AGNAlgernon Pharmaceuticals Inc
31/07/201912:22InvestorsHub NewsWireAlgernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) ...CSE:AGNAlgernon Pharmaceuticals Inc
29/07/201913:32InvestorsHub NewsWireAlgernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis ...CSE:AGNAlgernon Pharmaceuticals Inc
03/07/201914:06InvestorsHub NewsWireAlgernon Pharmaceuticals' NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56%CSE:AGNAlgernon Pharmaceuticals Inc
04/06/201913:00InvestorsHub NewsWireQ&A with Christopher J. Moreau CEO of Algernon PharmaceuticalsCSE:AGNAlgernon Pharmaceuticals Inc
28/05/201913:00InvestorsHub NewsWireAlgernon Pharmaceuticals: Join us for an interview with the CEO and CSOCSE:AGNAlgernon Pharmaceuticals Inc
23/05/201913:04InvestorsHub NewsWireRepurposing Drugs Reduces Investment Risk. Algernon Pharma Plans Phase 2 Trials for NASH, CKD and IBDCSE:AGNAlgernon Pharmaceuticals Inc
 Showing the most relevant articles for your search:CSE:AGN